Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock

Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are better predictors of septic shock severity. This approach may inform more appropriate treatment regimens and improve outcomes for these patients.

NCT Number	NCT06746753
Lead Sponsor	Wake Forest University Health Sciences Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions	Septic Shock
Enrollment	78 participants
Start Date	2026-09
Primary Completion	2028-09-30 (estimated)
Study Completion	2028-10-07 (estimated)
Updated on ClinicalTrials.gov	2026-07-24